25
Participants
Start Date
April 30, 2015
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2027
MRD-BMT with Fludarabine-based RIC for Acquired AA
"Fludarabine: Dose: 30mg/m2/day (\<10kg will receive 1mg/kg/day) Days: -7, -6, -5, -4, -3~Cyclophosphamide: Dose: 60mg/kg/day Days: -5, -4~Thymoglobulin: Dose: 3mg/kg/day Days: -4, -3, -2~Bone marrow infusion: Day 0"
MRD-BMT with Fludarabine-based RIC for iBMF with trilineage aplasia
"Fludarabine: Dose: 30mg/m2/day (\<10kg will receive 1mg/kg/day) Days: -7, -6, -5, -4, -3~Cyclophosphamide: Dose: 10 mg/kg/day Days: -6, -5, -4, -3~Thymoglobulin: Dose: 3mg/kg/day Days: -4, -3, -2~Bone marrow infusion: Day 0"
MRD-BMT with Fludarabine-based RIC for iBMF without trilineage aplasia
"Fludarabine: Dose: 30mg/m2/day (\<10kg will receive 1mg/kg/day) Days: -6, -5, -4, -3, -2~Busulfan: Dose: every 6 hours for a total of 12 doses with dosing adjustments to achieve a steady state concentration of 900-1200ng/mL OR daily for a total of 3 doses targeting AUC 3600-6000 (micromole/liter)\*minute Days: -7, -6, -5, -4~Thymoglobulin: Dose: 3mg/kg/day Days: -10, -9, -8~Bone marrow infusion: Day 0"
RECRUITING
Children's Hospital of Philadelphia, Philadelphia
Children's Hospital of Philadelphia
OTHER